Twist Bioscience Corp vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Twist Bioscience Corp trades at $158 (market cap $10.32B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.55 (market cap $339.46M). The key difference: Twist Bioscience Corp is far larger — about 30.4× Roundhill S&P 500 0DTE Covered Call Strategy ETF's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 54 Days on average.
| TWST | XDTE | |
|---|---|---|
Market Cap | $10.32B | $339.46M |
Volume | 5,894,998 | 214,614 |
Sector | Health | Income / Options Overlay |
52-Week High | $205.00 | $44.76 |
52-Week Low | $25.45 | $36.00 |
Typical Hold Time | 27 Days | 54 Days |
Enterprise Value | $10.24B | — |
Signals from Pluang's Aura AI — not financial advice
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →